{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:53:38Z","timestamp":1761947618367},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,5,14]],"date-time":"2010-05-14T00:00:00Z","timestamp":1273795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12032-010-9542-z","type":"journal-article","created":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T17:21:55Z","timestamp":1273771315000},"page":"43-52","source":"Crossref","is-referenced-by-count":21,"title":["Management of disease- and treatment-related complications in patients with multiple myeloma"],"prefix":"10.1007","volume":"27","author":[{"given":"Francesca","family":"Gay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,14]]},"reference":[{"key":"9542_CR1","first-page":"1426","volume-title":"Cecil textbook of medicine","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV, Kyle RA. Plasma Cell Disorders. In: Goldman L, Ausiello D, editors. Cecil textbook of medicine. 23rd ed. Philadelphia: W B Saunders; 2008. p. 1426\u201337.","edition":"23"},{"key":"9542_CR2","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860\u201373.","journal-title":"N Engl J Med"},{"issue":"2","key":"9542_CR3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","volume":"33","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33(2):86\u20139.","journal-title":"Am J Hematol"},{"issue":"3","key":"9542_CR4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.2007.11.6863","volume":"26","author":"W Bensinger","year":"2008","unstructured":"Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26(3):480\u201392.","journal-title":"J Clin Oncol"},{"key":"9542_CR5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825\u201331.","journal-title":"Lancet"},{"issue":"9594","key":"9542_CR6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial. Lancet. 2007;370(9594):1209\u201318.","journal-title":"Lancet"},{"issue":"22","key":"9542_CR7","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","volume":"27","author":"C Hulin","year":"2009","unstructured":"Hulin C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75\u00a0years with newly diagnosed multiple myeloma: IFM 01\/01 trial. J Clin Oncol. 2009;27(22):3664\u201370.","journal-title":"J Clin Oncol"},{"issue":"9","key":"9542_CR8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906\u201317.","journal-title":"N Engl J Med"},{"issue":"11","key":"9542_CR9","first-page":"77","volume":"110","author":"JA Zonder","year":"2007","unstructured":"Zonder JA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. ASH Annu Meet Abstr. 2007;110(11):77.","journal-title":"ASH Annu Meet Abstr"},{"issue":"1","key":"9542_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29\u201337.","journal-title":"Lancet Oncol"},{"issue":"11","key":"9542_CR11","first-page":"57","volume":"108","author":"M Macro","year":"2006","unstructured":"Macro M, et al. Dexamethasone\u00a0+\u00a0Thalidomide (Dex\/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. ASH Annu Meet Abstr. 2006;108(11):57.","journal-title":"ASH Annu Meet Abstr"},{"key":"9542_CR12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol. 2006;24:431\u20136.","journal-title":"J Clin Oncol"},{"key":"9542_CR13","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV, et al. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171\u20137.","journal-title":"J Clin Oncol"},{"issue":"11","key":"9542_CR14","first-page":"450","volume":"110","author":"JL Harousseau","year":"2007","unstructured":"Harousseau JL, et al. VELCADE\/Dexamethasone (Vel\/D) Versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005\/01 Trial. ASH Annu Meet Abstr. 2007;110(11):450.","journal-title":"ASH Annu Meet Abstr"},{"key":"9542_CR15","first-page":"2171","volume":"26","author":"A Spencer","year":"2009","unstructured":"Spencer A, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;26:2171\u20137.","journal-title":"J Clin Oncol"},{"issue":"10","key":"9542_CR16","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal M, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289\u201394.","journal-title":"Blood"},{"issue":"24","key":"9542_CR17","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"25","key":"9542_CR18","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","volume":"25","author":"RZ Orlowski","year":"2007","unstructured":"Orlowski RZ, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892\u2013901.","journal-title":"J Clin Oncol"},{"issue":"21","key":"9542_CR19","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133\u201342.","journal-title":"N Engl J Med"},{"issue":"21","key":"9542_CR20","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123\u201332.","journal-title":"N Engl J Med"},{"key":"9542_CR21","unstructured":"National Cancer Institute: Common Terminology Criteria for Adverse Events, v3.0, (CTCAE) http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_v3.0 ."},{"issue":"28","key":"9542_CR22","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","volume":"25","author":"A Palumbo","year":"2007","unstructured":"Palumbo A, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report From the GIMEMA Italian multiple myeloma network. J Clin Oncol. 2007;25(28):4459\u201365.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9542_CR23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","volume":"132","author":"A Smith","year":"2006","unstructured":"Smith A, Wisloff F, Samson D. UK myeloma forum; nordic myeloma study group; British committee for standards in haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132(4):410\u201351.","journal-title":"Br J Haematol"},{"key":"9542_CR24","first-page":"651","volume":"112","author":"M-V Mateos","year":"2008","unstructured":"Mateos M-V, et al. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent? Blood (ASH Annu Meet Abstr). 2008;112:651.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"9542_CR25","first-page":"652","volume":"112","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, et al. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood (ASH Annu Meet Abstr). 2008;112:652.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"9542_CR26","first-page":"3550","volume":"108","author":"DE Reece","year":"2006","unstructured":"Reece DE, et al. Lenalidomide (Revlimid\u00ae) \u00b1 corticosteroids in elderly patients with relapsed\/refractory multiple myeloma. Blood (ASH Annu Meet Abstr). 2006;108:3550.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"8","key":"9542_CR27","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","volume":"111","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968\u201377","journal-title":"Blood"},{"issue":"10","key":"9542_CR28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","volume":"82","author":"Lacy","year":"2007","unstructured":"Lacy MQ, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82(10):1179\u201384.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"9542_CR29","first-page":"3554","volume":"108","author":"AA Chanan-Khan","year":"2006","unstructured":"Chanan-Khan AA, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel\/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. ASH Annu Meet Abstr. 2006;108(11):3554.","journal-title":"ASH Annu Meet Abstr"},{"issue":"8","key":"9542_CR30","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/leu.2008.127","volume":"22","author":"MA Hussein","year":"2008","unstructured":"Hussein MA, et al. The role of vertebral augmentation in multiple myeloma: international myeloma working group consensus statement. Leukemia. 2008;22(8):1479\u201384.","journal-title":"Leukemia"},{"key":"9542_CR31","volume-title":"WHO guidelines: cancer pain relief","author":"WHO","year":"1986","unstructured":"WHO. WHO guidelines: cancer pain relief. 2nd ed. Geneva: World Health Organisation; 1986.","edition":"2"},{"issue":"5","key":"9542_CR32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0360-3016(93)90308-I","volume":"25","author":"BR Leigh","year":"1993","unstructured":"Leigh BR, Mack CF, Matzner MB, Shimm DS. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys. 1993;25(5):801\u20134.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"9542_CR33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","volume":"20","author":"E Terpos","year":"2009","unstructured":"Terpos E, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network. Ann Oncol. 2009;20(8):1303\u201317.","journal-title":"Ann Oncol"},{"issue":"2 Suppl","key":"9542_CR34","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2008.12.005","volume":"122","author":"SL Silverman","year":"2009","unstructured":"Silverman SL, Lendesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122(2 Suppl):S33\u201345.","journal-title":"Am J Med"},{"issue":"4","key":"9542_CR35","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92(4):546\u20139.","journal-title":"Haematologica"},{"issue":"17","key":"9542_CR36","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889\u201393.","journal-title":"Arch Intern Med"},{"issue":"4","key":"9542_CR37","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1046\/j.1523-1755.2001.00941.x","volume":"60","author":"SA Mezzano","year":"2001","unstructured":"Mezzano SA, et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60(4):1366\u201377.","journal-title":"Kidney Int"},{"key":"9542_CR38","unstructured":"Ltd C, inventor Revlimid\u00ae (lenalidomide) Product Information. Celgene Europe Limited. Berkshire, SL4 1NA UK. March 2009. Available from URL: http:\/\/emc.medicines.org.uk\/printfriendlydocument.aspx?documentid=19841&companyid=1868 2009."},{"issue":"4","key":"9542_CR39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLM.2008.n.031","volume":"8","author":"SJ Kim","year":"2008","unstructured":"Kim SJ, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma. 2008;8(4):237\u201340.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"5","key":"9542_CR40","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","volume":"50","author":"P Raanani","year":"2009","unstructured":"Raanani P, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50(5):764\u201372.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"9542_CR41","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","volume":"21","author":"J Blad\u00e9","year":"2007","unstructured":"Blad\u00e9 J. Complications of multiple myeloma. Hematol Oncol Clin North Am. 2007;21(6):1231\u201346.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"9542_CR42","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2141.2008.07573.x","volume":"144","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):890\u20135.","journal-title":"Br J Haematol"},{"issue":"5","key":"9542_CR43","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593\u20139.","journal-title":"Blood"},{"issue":"2","key":"9542_CR44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414\u201323.","journal-title":"Leukemia"},{"issue":"11","key":"9542_CR45","first-page":"649","volume":"112","author":"P Wijermans","year":"2008","unstructured":"Wijermans P, et al. Melphalan\u00a0+\u00a0Prednisone Versus Melphalan\u00a0+\u00a0Prednisone\u00a0+\u00a0Thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study. Blood (ASH Annu Meet Abstr). 2008;112(11):649.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"9542_CR46","first-page":"492","volume":"114","author":"A Palumbo","year":"2009","unstructured":"Palumbo A, et al. A phase III study of enoxaparin vs aspirin vs low-dose warfarin as thromboprophylaxis for newly diagnosed myeloma patients treated with thalidomide based-regimens. Blood (ASH Annu Meet Abstr). 2009;114:492.","journal-title":"Blood (ASH Annu Meet Abstr)"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9542-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9542-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9542-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:46Z","timestamp":1559442166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9542-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,14]]},"references-count":46,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["9542"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9542-z","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,14]]}}}